Skip to main content
x

Recent articles

More doubts swirl around Lumakras

With sales of the Amgen KRAS inhibitor flatlining an advisory panel is called to discuss its continued US approval.

Exelixis claims a label-expanding Cabo success at last

However, the design of the Contact-02 study, and the relevance of the positive PFS endpoint, will be debated.

A subcutaneous answer to PD-1’s patent problem

PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.

World Lung 2023 preview – Astra’s Tagrisso showdown

Flaura2 takes centre stage, while Trodelvy and dato square off in PD-1 combo trials.

Green light
A short-lived hold for Arcellx & Gilead

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

Astra goes pivotal with CTLA-4

Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.

Recent Quick take

Most Popular